NCT04991766

A Study of [¹⁴C]-LY3484356 in Healthy Female Participants

An Open-label, Two-part Study of the Disposition and Absolute Bioavailability of [¹⁴C]-LY3484356 in Healthy Females of Non-Childbearing Potential

• Status: Completed
• Phase: Phase 1
• Study type: Interventional
• Enrollment: 16 (actual)
• Sponsor: Eli Lilly and Company · Industry
• Sex: Female
• Age: 18 Years – 65 Years
• Healthy volunteers: Accepted

Summary

The main purpose of this study is to measure how much of the study drug gets into the bloodstream and how long it takes the body to get rid of it. This study has two parts. It will involve a single dose of 14C radiolabeled LY3484356. This means that a radioactive substance C14 will be incorporated into the study drug, to investigate the study drug and its breakdown products, to find out how much of these pass from blood into urine, feces and expired air. The study will last about 4 weeks. Screening is required within 28 days prior to the start of the study and follow up is required approximately 7 days after discharge.

Conditions

• Healthy

Interventions

Type	Name	Description
DRUG	[¹⁴C]-LY3484356	Administered orally.
DRUG	LY3484356	Administered orally.
DRUG	[¹⁴C]-LY3484356 (IV)	Administered IV.

Timeline

• Start date: 2021-08-13
• Primary completion: 2022-04-02
• Completion: 2022-04-02
• First posted: 2021-08-05
• Last updated: 2025-12-05
• Results posted: 2025-12-05

Locations

1 site across 1 country: United States

Regulatory

• FDA-regulated drug study